MODY4
MCID: MDY006
MIFTS: 30

Mody, Type Iv (MODY4) malady

Categories: Genetic diseases, Rare diseases

Aliases & Classifications for Mody, Type Iv

Aliases & Descriptions for Mody, Type Iv:

Name: Mody, Type Iv 54 13
Mody4 12 50 24 66
Mody Type 4 12 50 66
Maturity-Onset Diabetes of the Young Type 4 12 24
Maturity-Onset Diabetes of the Young 4 66 29
Maturity-Onset Diabetes of the Young, Type Iv 69
Maturity-Onset Diabetes of the Young, Type 4 50
Maturity-Onset Diabetes of the Young Type Iv 24
Type 4 Maturity-Onset Diabetes of the Young 50
Mody Insulin Promoter Factor-1 Related 50
Diabetes Mellitus, Mody Type 4 24
Diabetes Mellitus Mody Type 4 50
Mody-4 66

Characteristics:

HPO:

32
mody, type iv:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 606392
Disease Ontology 12 DOID:0111103
MedGen 40 C1833382
MeSH 42 D003924

Summaries for Mody, Type Iv

UniProtKB/Swiss-Prot : 66 Maturity-onset diabetes of the young 4: A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

MalaCards based summary : Mody, Type Iv, also known as mody4, is related to maturity-onset diabetes of the young and pancreatitis, and has symptoms including type ii diabetes mellitus and maturity-onset diabetes of the young. An important gene associated with Mody, Type Iv is PDX1 (Pancreatic And Duodenal Homeobox 1). The drugs Ethanol and Glyburide have been mentioned in the context of this disorder.

Disease Ontology : 12 A maturity-onset diabetes of the young that has material basis in mutation in the PDX1 gene on chromosome 13q12.2.

Description from OMIM: 606392

Related Diseases for Mody, Type Iv

Diseases related to Mody, Type Iv via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 maturity-onset diabetes of the young 10.9
2 pancreatitis 9.9

Symptoms & Phenotypes for Mody, Type Iv

Clinical features from OMIM:

606392

Human phenotypes related to Mody, Type Iv:

32
id Description HPO Frequency HPO Source Accession
1 type ii diabetes mellitus 32 HP:0005978
2 maturity-onset diabetes of the young 32 HP:0004904

Drugs & Therapeutics for Mody, Type Iv

Drugs for Mody, Type Iv (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
4
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
5
Testosterone Approved, Investigational Phase 4 58-22-0 6013
6
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
7
Fluvastatin Approved Phase 4 93957-54-1 1548972
8
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
9
Gliclazide Approved Phase 4,Phase 3,Phase 2 21187-98-4 3475
10
Glipizide Approved Phase 4,Phase 3 29094-61-9 3478
11
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1 93479-97-1 3476
12
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Amlodipine Approved Phase 4 88150-42-9 2162
15
Phenylephrine Approved Phase 4 59-42-7 6041
16
Oxymetazoline Approved Phase 4 1491-59-4 4636
17
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 56180-94-0 441184
18
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
19
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 1 141758-74-9 15991534
20
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 274901-16-5 6918537
21
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 361442-04-8 11243969
22
Liraglutide Approved Phase 4,Phase 3,Phase 1 204656-20-2
23
Voglibose Approved, Investigational Phase 4,Phase 3,Phase 2 83480-29-9 444020
24
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
25
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
26
Insulin Glargine Approved Phase 4,Phase 3,Phase 1 160337-95-1
27
Methyltestosterone Approved Phase 4 58-18-4 6010
28
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 850649-61-5 11450633
29
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 668270-12-0 10096344
30
Insulin Lispro Approved Phase 4,Phase 3,Phase 2 133107-64-9
31
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
32
Nitric Oxide Approved Phase 4 10102-43-9 145068
33
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 122320-73-4 77999
34
Verapamil Approved Phase 4 52-53-9 2520
35
Nateglinide Approved, Investigational Phase 4,Phase 3 105816-04-4 60026
36
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
37
Enalaprilat Approved Phase 4 76420-72-9 6917719
38
Trandolapril Approved Phase 4 87679-37-6 5484727
39
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
40
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
41 Lacidipine Approved Phase 4 103890-78-4
42
Acetylcholine Approved Phase 4 51-84-3 187
43
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
44
Adenosine Approved, Investigational Phase 4 58-61-7 60961
45
Regadenoson Approved Phase 4 313348-27-5 219024
46
Ziprasidone Approved Phase 4 146939-27-7 60854
47
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1 842133-18-0
48
Empagliflozin Approved Phase 4,Phase 3,Phase 2 864070-44-0
49
Insulin-glulisine Approved Phase 4,Phase 3 207748-29-6
50
Nitroprusside Approved Phase 4 15078-28-1 11963622

Interventional clinical trials:

(show top 50) (show all 838)
id Name Status NCT ID Phase
1 Rationale and Design for Shiga Microalbuminuria Reduction Trial Unknown status NCT00202618 Phase 4
2 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion Unknown status NCT02406443 Phase 4
3 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4
4 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4
5 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4
6 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4
7 Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress Unknown status NCT00699322 Phase 4
8 Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes Unknown status NCT01339143 Phase 4
9 Effect of Linagliptin on TRL Metabolism Unknown status NCT02280174 Phase 4
10 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4
11 The Swiss Glucose Variability Study Unknown status NCT01426737 Phase 4
12 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
13 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4
14 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4
15 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4
16 Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp" Unknown status NCT01660386 Phase 4
17 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4
18 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4
19 Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes Unknown status NCT01867502 Phase 4
20 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4
21 Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp Unknown status NCT02386943 Phase 4
22 Triple Therapy in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4
23 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4
24 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4
25 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4
26 Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin. Completed NCT02157298 Phase 4
27 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Contr Completed NCT02243176 Phase 4
28 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes Completed NCT01472432 Phase 4
29 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus Completed NCT02426541 Phase 4
30 A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients. Completed NCT02533453 Phase 4
31 The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes Completed NCT01181986 Phase 4
32 Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Completed NCT01766778 Phase 4
33 Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes Completed NCT01006590 Phase 4
34 MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes Completed NCT01847144 Phase 4
35 Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin Completed NCT01006603 Phase 4
36 Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes Completed NCT02081599 Phase 4
37 Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea Completed NCT00328965 Phase 4
38 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Completed NCT02471404 Phase 4
39 Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy Completed NCT01972724 Phase 4
40 Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure Completed NCT01461577 Phase 4
41 Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus Completed NCT01449747 Phase 4
42 SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies Completed NCT01744236 Phase 4
43 Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications Completed NCT01107886 Phase 4
44 Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D Completed NCT02607410 Phase 4
45 Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes Completed NCT01309698 Phase 4
46 Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus Completed NCT01169818 Phase 4
47 Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diab Completed NCT01045590 Phase 4
48 Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. Completed NCT01122979 Phase 4
49 Neuroendocrine Brake for Type 2 Diabetes Mellitus Completed NCT00450710 Phase 4
50 Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine Completed NCT02200991 Phase 4

Search NIH Clinical Center for Mody, Type Iv

Genetic Tests for Mody, Type Iv

Genetic tests related to Mody, Type Iv:

id Genetic test Affiliating Genes
1 Maturity-Onset Diabetes of the Young, Type 4 29
2 Maturity-Onset Diabetes of the Young Type 4 24 PDX1

Anatomical Context for Mody, Type Iv

Publications for Mody, Type Iv

Variations for Mody, Type Iv

UniProtKB/Swiss-Prot genetic disease variations for Mody, Type Iv:

66
id Symbol AA change Variation ID SNP ID
1 PDX1 p.Cys18Arg VAR_009309 rs137852785
2 PDX1 p.Gln59Leu VAR_009310 rs137852784
3 PDX1 p.Arg197His VAR_009312 rs137852786

ClinVar genetic disease variations for Mody, Type Iv:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PDX1 PDX1, 1-BP DEL, 188C deletion Pathogenic
2 PDX1 NM_000209.3(PDX1): c.442C> G (p.Arg148Gly) single nucleotide variant Likely pathogenic rs193922355 GRCh37 Chromosome 13, 28498428: 28498428
3 PDX1 NM_000209.3(PDX1): c.571A> C (p.Lys191Gln) single nucleotide variant Likely pathogenic rs193922356 GRCh37 Chromosome 13, 28498557: 28498557
4 PDX1 NM_000209.3(PDX1): c.773A> G (p.Glu258Gly) single nucleotide variant Likely pathogenic rs193922360 GRCh37 Chromosome 13, 28498759: 28498759

Expression for Mody, Type Iv

Search GEO for disease gene expression data for Mody, Type Iv.

Pathways for Mody, Type Iv

GO Terms for Mody, Type Iv

Sources for Mody, Type Iv

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....